Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Spotlight

GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines

Business

Deals
Earnings
Manufacturing

Policy & Regulation

Regulatory Landscape
Drug Pricing
IP & Litigation

Tools & Trackers

What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings

Conference Coverage

Partner Insights

Generics Bulletin Perspectives

Exploring market-shifting topics for the off-patent sector.

Medtech Insight

Generics Bulletin

Sandoz: Big Cap Biosimilar Rivals Lack Clarity On Commitment

Comments Follow Plans For Novartis To Spin Sandoz

Oct 03 2022

• By Dean Rudge

Timeline years 2025 blue pin — Sandoz has outlined launches up to 2025 and beyond • Source: Olivier Le Moal / Alamy Stock Photo

Related Content

Sandoz Delivers Denosumab Data As Biogen Sues On Tysabri

Sep 23 2022

EMA And HMA Speak Out In Favor Of Biosimilar Interchangeability

Sep 22 2022

Novartis Will Not Split Biosimilars From Sandoz As Part Of Review

Feb 03 2022

Sandoz: US Oral Solids And Injectables Have Reached Bottom

Aug 26 2022

Sandoz Set To Become Public Company In 2023 As Novartis Confirms Spin-Off

Aug 25 2022

Related Companies

Sandoz Inc.

Additional Topics

International Biosimilars Strategy Regulation BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About

About UsOpens in new window
Meet the Team
AdvertiseOpens in new window
Contact Us

Account

My Account
My View
Email Preferences
Start Free TrialOpens in new window

More

Generics Top 50 Ranking
Biosimilars
Generics
Value Added Medicines

Terms and Conditions Opens in new window

Privacy PolicyOpens in new window